StreetInsider

• Log in to your account:

  
  Log in
• Signup
• Home
• EPS Insider
• Event Calendar
• Conferences
• Classic Site

Upgrade to SI Premium - Free Trial

Revance Therapeutics (RVNC)

Form 4 Revance Therapeutics, For: Apr 16 Filed by: Jordan Erica April 17, 2024 4:35 PM - SEC Filing Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting April 12, 2024 8:00 AM - BizWire Form SC 13G/A Revance Therapeutics, Filed by: JPMORGAN CHASE & CO April 9, 2024 1:18 PM - SEC Filing Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 27, 2024 4:05 PM - BizWire Form DEFA14A Revance Therapeutics, March 21, 2024 4:10 PM - SEC Filing Form DEF 14A Revance Therapeutics, For: May 01 March 21, 2024 4:08 PM - SEC Filing Form 4 Revance Therapeutics, For: Mar 15 Filed by: Sjuts Dustin S March 19, 2024 6:46 PM - SEC Filing Form 4 Revance Therapeutics, For: Mar 15 Filed by: Moxie Dwight March 19, 2024 6:45 PM - SEC Filing Form 4 Revance Therapeutics, For: Mar 15 Filed by: Schilke Tobin March 19, 2024 6:44 PM - SEC Filing Form 4 Revance Therapeutics, For: Mar 15 Filed by: Foley Mark J March 19, 2024 6:43 PM - SEC Filing Form 144 Revance Therapeutics, Filed by: Sjuts Dustin S March 18, 2024 6:17 AM - SEC Filing Form 144 Revance Therapeutics, Filed by: Schilke Tobin March 18, 2024 6:14 AM - SEC Filing Form 144 Revance Therapeutics, Filed by: Moxie Dwight March 18, 2024 6:10 AM - SEC Filing Form 4 Revance Therapeutics, For: Mar 06 Filed by: Foley Mark J March 8, 2024 4:33 PM - SEC Filing Form 8-K Revance Therapeutics, For: Mar 04 March 5, 2024 5:08 PM - SEC Filing Form 424B5 Revance Therapeutics, March 5, 2024 5:01 PM - SEC Filing Form 4 Revance Therapeutics, For: Feb 29 Filed by: Sjuts Dustin S March 4, 2024 5:35 PM - SEC Filing Form 4 Revance Therapeutics, For: Feb 29 Filed by: Moxie Dwight March 4, 2024 5:34 PM - SEC Filing Form 4 Revance Therapeutics, For: Feb 29 Filed by: Schilke Tobin March 4, 2024 4:45 PM - SEC Filing Form 4 Revance Therapeutics, For: Feb 29 Filed by: Foley Mark J March 4, 2024 4:34 PM - SEC Filing Revance Therapeutics (RVNC) Prices 16M Share Offering at $6.25/sh March 4, 2024 9:26 AM - StreetInsider Revance Announces Pricing of $100.0 Million Public Offering of Common Stock March 4, 2024 9:25 AM - BizWire Form 424B5 Revance Therapeutics, March 4, 2024 6:40 AM - SEC Filing Revance Therapeutics (RVNC) Announces Proposed $100M Share Offering March 4, 2024 6:38 AM - StreetInsider Revance Announces Proposed Public Offering of Common Stock March 4, 2024 6:37 AM - BizWire Revance Therapeutic (RVNC) PT Lowered to $9 at Morgan Stanley March 1, 2024 9:04 AM - StreetInsider Revance Therapeutic (RVNC) PT Raised to $9 at Goldman Sachs March 1, 2024 6:34 AM - StreetInsider Form 3 Revance Therapeutics, For: Feb 27 Filed by: Jordan Erica February 29, 2024 4:39 PM - SEC Filing Form 3 Revance Therapeutics, For: Feb 27 Filed by: Hollander David February 29, 2024 4:38 PM - SEC Filing Revance Therapeutic (RVNC) PT Lowered to $18 at Needham February 29, 2024 7:49 AM - StreetInsider Revance Therapeutic (RVNC) PT Lowered to $20 at Piper Sandler February 29, 2024 7:29 AM - StreetInsider Form S-8 Revance Therapeutics, February 29, 2024 6:19 AM - SEC Filing Form 10-K Revance Therapeutics, For: Dec 31 February 28, 2024 6:00 PM - SEC Filing Revance Therapeutics (RVNC) Tops Q4 EPS by 3c, provides product guidance February 28, 2024 4:21 PM - StreetInsider Form 8-K Revance Therapeutics, For: Feb 23 February 28, 2024 4:10 PM - SEC Filing Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update February 28, 2024 4:05 PM - BizWire Revance Therapeutic (RVNC) PT Lowered to $12 at H.C. Wainwright February 26, 2024 6:37 AM - StreetInsider Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 February 21, 2024 8:01 AM - BizWire Revance to Participate in Upcoming Investor Conferences February 21, 2024 8:00 AM - BizWire Form SC 13G/A Revance Therapeutics, Filed by: Palo Alto Investors LP February 14, 2024 4:56 PM - SEC Filing Form SC 13G/A Revance Therapeutics, Filed by: Antara Capital LP February 14, 2024 3:45 PM - SEC Filing Form SC 13G/A Revance Therapeutics, Filed by: VANGUARD GROUP INC February 13, 2024 6:01 PM - SEC Filing Form 8-K Revance Therapeutics, For: Feb 07 February 13, 2024 4:29 PM - SEC Filing Form SC 13G/A Revance Therapeutics, Filed by: Polar Capital Holdings Plc February 13, 2024 9:39 AM - SEC Filing Form SC 13G/A Revance Therapeutics, Filed by: Capital World Investors February 9, 2024 6:22 PM - SEC Filing Form SC 13G/A Revance Therapeutics, Filed by: GIC Private Ltd February 9, 2024 10:07 AM - SEC Filing Form 8-K Revance Therapeutics, For: Jan 31 February 6, 2024 4:05 PM - SEC Filing Form SC 13G Revance Therapeutics, Filed by: FRANKLIN RESOURCES INC February 6, 2024 1:58 PM - SEC Filing Form 4 Revance Therapeutics, For: Jan 31 Filed by: Moxie Dwight February 2, 2024 4:48 PM - SEC Filing Form 4 Revance Therapeutics, For: Jan 31 Filed by: Schilke Tobin February 2, 2024 4:47 PM - SEC Filing Form 4 Revance Therapeutics, For: Jan 31 Filed by: Foley Mark J February 2, 2024 4:46 PM - SEC Filing Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology® February 2, 2024 8:00 AM - BizWire Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference February 1, 2024 8:00 AM - BizWire Mizuho Securities Downgrades Revance Therapeutic (RVNC) to Neutral January 29, 2024 4:31 AM - StreetInsider Revance Therapeutic (RVNC) PT Lowered to $10 at Barclays January 29, 2024 4:17 AM - StreetInsider Form SC 13G/A Revance Therapeutics, Filed by: BlackRock Inc. January 25, 2024 1:50 PM - SEC Filing Form SC 13G/A Revance Therapeutics, Filed by: JPMORGAN CHASE & CO January 25, 2024 11:11 AM - SEC Filing Form SC 13G/A Revance Therapeutics, Filed by: JPMORGAN CHASE & CO January 25, 2024 11:11 AM - SEC Filing Full Article List